Monday March 17, 9:07 am ET
"Brent Pierce is neither a director nor officer of ICI."
Source: Investor Communications International, Inc., 17 Mar 2003
EXECUTED to be effective as of the 6th day of February, 2003
Date: February __, 2003 Investor Communications
International, Inc.
By: Brent Pierce, President
-------------------------------
http://www.secinfo.com/$/SEC/Page.asp?P=1050502-2-1084-1-28-166066
BLAINE, Wash., March 17 /PRNewswire/ -- Investor Communications International, Inc. ("ICI") announced that on March 14, 2003 Steven D. Jones and Carol S. Remond ("Steve&Carol") created another article that appeared in a Dow Jones news wire in the same erroneous vein as a previous inaccurate news wire by Steve&Carol of October 11, 2002 pertaining to ICI and GeneMax Corp. (OTC Bulletin Board: GMXX - News) that provide the reader with inaccurate and false facts and erroneous conclusions.
Although Steve&Carol seemed to stop writing defamatory and incorrect articles about ICI and GeneMax Corp. for a period of time after ICI made public that December 9, 2002 and October 11, 2002 news wires by Steve&Carol contained numerous unfactual statements, Steve&Carol have begun writing inaccurate reports that mislead the public. For those who may have forgotten, GeneMax Corp. and Investor Communications International, Inc. formed the subject of the news wire story dated October 11, 2002 by Steve&Carol. There were at least sixteen inaccurate facts or statements made in the October 11, 2002 news wire story by Steve&Carol. There were only 990 words in the entire October 11, 2002 Steve&Carol news wire. Corrections were brought to the attention of the lead author Steven D. Jones and counsel to Dow Jones with request for retraction. Retractions were not subsequently made.
Further information obtained by Steve&Carol pertaining to a lawsuit filed in the Superior Court of the State of Washington against a GeneMax shareholder, Garth Braun (the "Lawsuit"), has led to numerous erroneous statements by Steve&Carol. In fact, ICI would like to make clear that all conclusions made by Steve&Carol in their latest March 14, 2003 Dow Jones news wire pertaining to information they have received relating to the Lawsuit are false and untrue, proving once and for all that a little knowledge is a dangerous thing. Like the October 11, 2002 news wire by Steve&Carol that contained at least sixteen inaccurate facts or statements, it would be too onerous to address and disclose the breadth and effect of the numerous inaccuracies in the March 14, 2003 Dow Jones news wire, or correct the inaccurate and untrue conclusions made therein. As a result ICI provides clarification as follows:
-- All statements and conclusions made by Steve&Carol in the
March 14, 2003 Dow Jones news wire regarding the float of GeneMax
being larger than it was in October of last year or at any other
time stated in the article are false and untrue.
-- All statements and conclusions made by Steve&Carol in the
March 14, 2003 Dow Jones news wire regarding share options granted
to ICI in the capital of GeneMax Corp. and any sale thereto are
false and untrue.
-- Information provided to Dow Jones reporter last fall by Grant Atkins
of GeneMax Corp. is accurate and correct. That information has been
misquoted, misstated, taken out of context, or generally distorted
by Steve Jones for purposes other than providing true and accurate
reporting.
-- Brent Pierce is neither a director nor officer of ICI. Steve Jones
has been advised of such facts in writing, but chooses to distort
and misguide the public by making false statements to the contrary.
Grant Atkins of GeneMax Corp. stated, "When it comes to yellow journalism, Steven D. Jones and Carol S. Remond are likely to be involved. Companies are guided by SEC regulations and ever-increasing public governance. It is amazing that the media is guided by no governing body other than ethical constraints of journalistic professionalism. When authors lose that, they mislead the public. In the case of Remond and Jones, freedom of the press includes the freedom to mislead."
SAFE HARBOR STATEMENT
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN."
http://biz.yahoo.com/prnews/030317/sfm094_1.html
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM